Gene Editing Therapy Shows Promising Success For Sickle Cell Treatment

A new treatment for sickle cell disease could provide a functional cure for patients suffering from severe pain.

Apr. 2, 2026 at 7:50pm

Got story updates? Submit your updates here. ›

A ghostly, translucent X-ray photograph revealing the delicate internal structure of a healthy red blood cell, glowing against a dark background and conceptually representing the potential of gene-editing technology to treat sickle cell disease.A new gene-editing therapy offers hope for a functional cure to the devastating effects of sickle cell disease.Cleveland Today

Researchers have published findings in the New England Journal of Medicine regarding a new treatment called 'reni-cel' that uses gene-editing technology to fix a patient's own stem cells and produce more fetal hemoglobin, a type of protein that keeps red blood cells round and flexible. In a clinical trial, 27 out of 28 patients stayed completely free of painful sickle cell crises after the procedure, which doctors are calling a 'functional cure' for the disease.

Why it matters

Sickle cell disease is notoriously hard to treat, as it causes the body to produce misshapen, sickle-shaped blood cells that get stuck in vessels, leading to severe pain and organ damage. Current treatments usually require a high-risk bone marrow transplant, but this new gene-editing therapy uses the patient's own cells, eliminating the risk of rejection.

The details

The treatment involves collecting the patient's stem cells, using CRISPR technology to edit them to produce more fetal hemoglobin, and then infusing the repaired cells back into the patient's body after chemotherapy to clear out the old bone marrow. Within six months, patients saw their hemoglobin levels jump from a low average of 9.8 g/dL to 13.8 g/dL—levels very close to those of someone without the disease.

  • The findings were recently published in the New England Journal of Medicine.

The players

Rabi Hanna, M.D.

The lead author of the study and chair of the Pediatric Hematology – Oncology & Blood and Bone Marrow Transplant Division at Cleveland Clinic Children's.

Cleveland Clinic Children's

The medical institution where the clinical trial was conducted.

Got photos? Submit your photos here. ›

What they’re saying

“We have seen that a benefit of this CRISPR/Cas12a gene-editing technology is that there is no rejection, so it's different from traditional bone marrow transplants, which is standard treatment for sickle cell patients currently. Our aim has been to achieve a functional cure to help prevent any future damage caused by sickle cell disease, and these latest results are compelling.”

— Rabi Hanna, M.D., Lead author and chair of the Pediatric Hematology – Oncology & Blood and Bone Marrow Transplant Division at Cleveland Clinic Children's

What’s next

Researchers plan to continue studying the long-term effects and safety of the gene-editing therapy, with the goal of eventually making it available as a standard treatment option for sickle cell patients.

The takeaway

This new gene-editing therapy represents a major breakthrough in the treatment of sickle cell disease, offering the potential for a functional cure that could dramatically improve the quality of life for those living with this debilitating condition.